Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02640729 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating Nelotanserin for Treatment of Visual Hallucinations in Subjects With Lewy Body Dementia
A Phase 2 study of Lewy Body Dementia and Visual Hallucinations, sponsored by Axovant Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 10
- Study locations
NCT02640729: Completed Phase 2 study of Lewy Body Dementia and Visual Hallucinations, sponsored by Axovant Sciences.
NCT02640729 is a Phase 2 study of Lewy Body Dementia and Visual Hallucinations that has completed, run by Axovant Sciences. The registered enrollment target is 30 participants, below the 485-participant average among 8 other Lewy Body Dementia trials with a reported enrollment target (94% lower). The trial reports 10 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02640729, a Phase 2 study of Lewy Body Dementia and Visual Hallucinations, has completed, sponsored by Axovant Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 10
- Study locations
Study Summary
This study seeks to evaluate safety and efficacy of Nelotanserin for the treatment of visual hallucinations in subjects with Lewy body dementia.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Nelotanserin
Study Locations (10)
Florida
- US114 - Boca Raton
- US113 - Orlando
Ohio
- US104 - Cleveland
- US105 - Columbus
California
- US123 - Fountain Valley
Kansas
- US132 - Lenexa
Minnesota
- US103 - Rochester
Nebraska
- US129 - Lincoln
North Carolina
- US101 - Chapel Hill
Texas
- US131 - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2015-12 |
| Est. Completion | 2017-11 |
| Phase | Phase 2 |
What the finished NCT02640729 record still lists
NCT02640729 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 485-participant average among 8 other Lewy Body Dementia trials with a reported enrollment target (94% lower).
The record links to 2 conditions, with Lewy Body Dementia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02640729 lists 10 locations in 8 states (Florida, Ohio, California).
Frequently Asked Questions
What is clinical trial NCT02640729 about?
NCT02640729 is a clinical study titled "Study Evaluating Nelotanserin for Treatment of Visual Hallucinations in Subjects With Lewy Body Dementia". This study seeks to evaluate safety and efficacy of Nelotanserin for the treatment of visual hallucinations in subjects with Lewy body dementia.
What is the current status of trial NCT02640729?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2015-12. Estimated completion is 2017-11.
What conditions does trial NCT02640729 study?
This clinical trial studies the following conditions: Lewy Body Dementia, Visual Hallucinations.
What interventions are being tested in trial NCT02640729?
The interventions under investigation include: Placebo (DRUG), Nelotanserin (DRUG).
Who is sponsoring clinical trial NCT02640729?
This trial is sponsored by Axovant Sciences, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02640729 being conducted?
This trial has 10 study locations across California, Florida, Kansas, Minnesota, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lewy Body Dementia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02640729's enrollment target sits among peer trials
30 9th of 8 the lowest of 8 other Lewy Body Dementia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lewy Body Dementia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pulsed Electromagnetic Field Treatment With Dementia Patients
RECRUITING · NA
-
North American Prodromal Synucleinopathy Consortium Stage 2
RECRUITING
-
Retinal Imaging in Neurodegenerative Disease
RECRUITING
-
Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
RECRUITING
-
Environmental and Reproductive Health Risk for Lewy Body Dementia
ACTIVE NOT RECRUITING
-
PERSEVERE: Peer Mentor Support and Caregiver Education in Lewy Body Dementia
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia